{"pmid":32454408,"title":"COVID-19 as a STING disorder with delayed over-secretion of interferon-beta.","text":["COVID-19 as a STING disorder with delayed over-secretion of interferon-beta.","EBioMedicine","Berthelot, Jean-Marie","Liote, Frederic","32454408"],"journal":"EBioMedicine","authors":["Berthelot, Jean-Marie","Liote, Frederic"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32454408","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.ebiom.2020.102801","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667881798533644289,"score":9.490897,"similar":[{"pmid":32443163,"title":"Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta.","text":["Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta.","The pharmacological and immunological properties of interferons, especially those of interferon beta, and the corresponding treatment strategies are described, and the results of studies with different interferons in coronavirus infections are analysed. Furthermore, the data obtained with high-dosed native interferon beta in life-threatening acute viral diseases as well as the results of clinical pilot studies with high-dosed recombinant interferon beta-1a are provided because they serve as the rationale for the proposed therapeutic regimen to be applied in acute viral infections. This regimen differs from those approved for treatment of multiple sclerosis and consists of interferon beta-1a administered as a 24 hour intravenous infusion at a daily dose of up to 90 microg for 3-5 consecutive days. Since under this regimen transient severe side effects can occur, it is analysed which patients are suitable for this kind of treatment in general and if patients with severe coronavirus infections could also be treated accordingly.","Drug Res (Stuttg)","Brzoska, Josef","von Eick, Harald","Hundgen, Manfred","32443163"],"abstract":["The pharmacological and immunological properties of interferons, especially those of interferon beta, and the corresponding treatment strategies are described, and the results of studies with different interferons in coronavirus infections are analysed. Furthermore, the data obtained with high-dosed native interferon beta in life-threatening acute viral diseases as well as the results of clinical pilot studies with high-dosed recombinant interferon beta-1a are provided because they serve as the rationale for the proposed therapeutic regimen to be applied in acute viral infections. This regimen differs from those approved for treatment of multiple sclerosis and consists of interferon beta-1a administered as a 24 hour intravenous infusion at a daily dose of up to 90 microg for 3-5 consecutive days. Since under this regimen transient severe side effects can occur, it is analysed which patients are suitable for this kind of treatment in general and if patients with severe coronavirus infections could also be treated accordingly."],"journal":"Drug Res (Stuttg)","authors":["Brzoska, Josef","von Eick, Harald","Hundgen, Manfred"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32443163","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1055/a-1170-4395","topics":["Treatment"],"weight":1,"_version_":1667523504887562240,"score":49.497},{"pmid":32447232,"title":"COVID-19: beta-thalassemia subjects immunised?","text":["COVID-19: beta-thalassemia subjects immunised?","The novel coronavirus pneumonia (COVID-19) is a contagious acute respiratory infectious disease whose causative agent has been demonstrated to be a novel virus of the coronavirus family, SARSCoV-2. A recent PRE-print study has showed a heme attack on the 1-beta chain of hemoglobin by COVID19. Beta-thalassemia results of a default in the hemoglobin beta-chain synthesis. 1,5% global population are heterozygotes for this disease. In this study, by a multiple linear regression, we have analyzed the evolution of COVID-19 infection in three Italian regions (Puglia, Sardinia, Sicilia) with different beta-thalassemic prevalences, in order to search a link. The results have showed that betathalassemic heterozygote population prevalence is correlated to immunity against COVID-19, by a regression. This paper is only for academic discussion, the hypotheses and conclusions needs to be confirmed by further research.","Med Hypotheses","Lansiaux, Edouard","Pebay, Philippe Pierre","Picard, Jean-Laurent","Son-Forget, Joachim","32447232"],"abstract":["The novel coronavirus pneumonia (COVID-19) is a contagious acute respiratory infectious disease whose causative agent has been demonstrated to be a novel virus of the coronavirus family, SARSCoV-2. A recent PRE-print study has showed a heme attack on the 1-beta chain of hemoglobin by COVID19. Beta-thalassemia results of a default in the hemoglobin beta-chain synthesis. 1,5% global population are heterozygotes for this disease. In this study, by a multiple linear regression, we have analyzed the evolution of COVID-19 infection in three Italian regions (Puglia, Sardinia, Sicilia) with different beta-thalassemic prevalences, in order to search a link. The results have showed that betathalassemic heterozygote population prevalence is correlated to immunity against COVID-19, by a regression. This paper is only for academic discussion, the hypotheses and conclusions needs to be confirmed by further research."],"journal":"Med Hypotheses","authors":["Lansiaux, Edouard","Pebay, Philippe Pierre","Picard, Jean-Laurent","Son-Forget, Joachim"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32447232","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/j.mehy.2020.109827","keywords":["beta thalassemia","correlation","favipiravir","heme","immunization","italy","novel coronavirus","regression","respiratory distress","sardinia","statistics"],"locations":["Italian","Sardinia","Sicilia"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667698385854922754,"score":45.51879},{"pmid":32398300,"title":"Will Children Reveal their Secret? The Coronavirus Dilemma.","text":["Will Children Reveal their Secret? The Coronavirus Dilemma.","Eur Respir J","Porter, George James","32398300"],"journal":"Eur Respir J","authors":["Porter, George James"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32398300","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1183/13993003.01382-2020","topics":["Mechanism","Treatment"],"weight":1,"_version_":1666714494900895744,"score":44.90932},{"pmid":32388480,"title":"Can beta-adrenergic blockers be used in the treatment of COVID-19?","text":["Can beta-adrenergic blockers be used in the treatment of COVID-19?","Med Hypotheses","Vasanthakumar, Natesan","32388480"],"journal":"Med Hypotheses","authors":["Vasanthakumar, Natesan"],"date":"2020-05-11T11:00:00Z","year":2020,"_id":"32388480","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.mehy.2020.109809","keywords":["ace2","ards","beta-adrenergic blockers","covid-19","sars-cov-2","septic shock"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666428892614754305,"score":43.91186},{"pmid":32446335,"title":"Food insecurity will be the sting in the tail of COVID-19.","text":["Food insecurity will be the sting in the tail of COVID-19.","Lancet Glob Health","The Lancet Global Health","32446335"],"journal":"Lancet Glob Health","authors":["The Lancet Global Health"],"date":"2020-05-25T11:00:00Z","year":2020,"_id":"32446335","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1016/S2214-109X(20)30228-X","topics":["Prevention"],"weight":1,"_version_":1667698385910497280,"score":41.526535}]}